The respiratory virus SARS-CoV-2, responsible for the multisystem illness known as COVID-19 that resulted in the pandemic of 2020, is increasingly recognized for its ability to cause cerebrovascular complications. This series of four cases observed during the height of the pandemic in a single institution is presented to illustrate the diverse pathophysiology of COVID-19 cerebrovascular manifestations and their corresponding clinical and radiologic manifestations.

Purpose

The goal of this study was to introduce a new noncontrast enhanced 4D dynamic MR angiography (dMRA) technique termed multibolus TrueFISP-based spin tagging with alternating radiofrequency (TrueSTAR).

Methods

Multibolus TrueFISP-based spin tagging with alternating radiofrequency was developed by taking advantage of the phenomenon that the steady-state signal of TrueFISP is minimally disturbed by periodically inserted magnetization preparations (e.g., spin tagging) that are sandwiched by two α/2 RF pulses. Both theoretical analysis and experimental studies were carried out to optimize the proposed method which was compared with both pulsed and pseudo-continuous arterial spin labeling-based dMRA in healthy volunteers. Optimized multibolus dMRA was also applied in a patient with arteriovenous malformation to demonstrate its potential clinical utility.

Results

Multibolus dMRA offered a prolonged tagging bolus compared to the standard single-bolus dMRA, and allowed improved visualization of the draining veins in the arteriovenous malformation patient. Compared to pseudo-continuous arterial spin labeling-based dMRA, multibolus dMRA provided visualization of the full passage of the labeled blood with the flexibility for both static and dynamic magnetic resonance angiography.

Conclusion

By combining the benefits of pulsed and pseudo-continuous arterial spin labeling-based dMRA, multibolus TrueFISP-based spin tagging with alternating radiofrequency can prolong and enhance the tagging bolus without sacrificing imaging speed or temporal resolution.

Medial temporal atrophy is a well-established marker for Alzheimer’s disease (AD). However, due to normal variation in the size of medial temporal structures and variability in how radiologists interpret images, the use of clinical reads in establishing the presence of pathological atrophy is imprecise. A limitation of studies of magnetic resonance imaging (MRI) measures in AD is diagnostic uncertainty as it can be unknown if pre- or early-symptomatic subjects go on to develop AD and most subjects do not undergo autopsy verification of the diagnosis. In persons with or at-risk for AD due to fully-penetrant autosomal dominant mutations in the PSEN1 and APP genes, the diagnosis or future development of AD can be predicted with essentially 100% accuracy. We used this predictability to assess the ability of radiologists to detect hippocampal atrophy (HA) in persons destined to develop AD. Coronal T1-weighted MRI scans of 39 persons demented from (n = 4) or at-risk for inheriting (n = 35) PSEN1 or APP mutations were independently assessed by two radiologists and the presence or absence of HA determined. Of the 39 subjects, 26 were FAD mutation carriers. Fifteen of 28 asymptomatic at-risk persons were FAD mutation carriers and four of these were rated as having atrophy for a sensitivity of 27% and a specificity of 85%. Among seven mildly affected yet non-demented subjects, atrophy was detected in three and in the four demented subjects HA was identified in two. Our results suggest that radiologists’ ability to detect HA in persons in whom the diagnosis of incipient AD is certain is sub-optimal and quantitative MRI techniques or other biological markers of the disease are needed.

Vigabatrin, the first therapeutic agent to be approved by the Food and Drug Administration for the treatment of infantile spasms, as well as for adjunctive use in the treatment of refractory complex partial epilepsy, represents an important advance for patients with difficult-to-manage epilepsy. This review summarizes the complex history, chemistry, and pharmacology, as well as the clinical data leading to the approval of vigabatrin for infantile spasms in the US. The long path to its approval reflects the visual system and white matter toxicity concerns with this agent. This review provides a brief description of these concerns, and the regulatory safety monitoring and mitigation systems that have been put in place to enhance benefit over risk.

A single center magnetic resonance spectroscopy (MRS) imaging and surgical outcome study involving sixteen patients with cervical spondylotic myelopathy (CSM).In the present study, we assess the utility of MRS to quantify metabolic changes within the spinal cord and predict surgical outcome in CSM patients.MRS is an advanced spinal imaging modality that can provide pertinent metabolic and biochemical information regarding spinal cord function. Previous studies have demonstrated significant abnormalities in specific cellular metabolite concentrations in CSM patients.Sixteen patients with CSM were evaluated. Single voxel MRS was performed in the cervical cord. NAA and choline metabolite concentration ratios with respect to creatine were quantified, as well as the presence or absence of a lactate peak. The mJOA scale was used as the functional assessment measure. Correlation of MRS metabolites with change in mJOA score was performed.The mean follow-up time was 19 months. There was a statistically significant improvement between mean preoperative and postoperative mJOA score following surgery (P<0.0001). The NAA/Cr ratio demonstrated a significant relationship to the change in mJOA score after surgery (P=0.0479; R=0.2513). The Cho/NAA ratio demonstrated an even stronger correlation with the change in mJOA score following surgery (P=0.0065; R=0.4219). Neither the Cho/Cr ratio, nor the presence of a lactate peak or T2 weighted signal change was significantly correlated with change in mJOA score after surgery.MRS is a novel, noninvasive imaging modality that provides pertinent information regarding spinal cord cellular and metabolic function. In a cohort of operatively treated CSM patients, the NAA/Cr and Cho/NAA ratios were predictive of neurological outcome, as both were significantly associated with change in mJOA score after surgery.

BACKGROUND CONTEXT: Magnetic resonance imaging (MRI) is the standard imaging modality for the assessment of cervical spinal cord; however, MRI assessment of the spinal cord in cervical spondylotic myelopathy patients has not demonstrated a consistent association with neurologic function or outcome after surgical or medical intervention. Thus, there is a need for sensitive imaging biomarkers that can predict functional impairment in patients with advanced cervical spondylosis. PURPOSE: To implement diffusion tensor imaging (DTI) as an imaging biomarker for microstructural integrity and functional impairment in patients with cervical spondylosis. STUDY DESIGN: Nonrandomized, single institution study. PATIENT SAMPLE: Forty-eight cervical spondylosis patients with or without spinal cord signal change underwent DTI of the spinal cord along with functional assessment. OUTCOME MEASURES: Functional measures of neurologic function via modified Japanese Orthopedic Association (mJOA) score. METHODS: A zoomed-echoplanar imaging technique and two-dimensional spatially selective radiofrequency excitation pulse were used for DTI measurement. Fractional anisotropy (FA), mean diffusivity (MD), radial and axial diffusion (AD) coefficient, AD anisotropy, ψ, defined as AD-MD, and the standard deviation (SD) of primary eigenvector orientation were evaluated at the site of compression. RESULTS: Results suggest average FA, transverse apparent diffusion coefficient, ψ, and SD of primary eigenvector orientation at the spinal level of highest compression were linearly correlated with mJOA score. Receiver-operator characteristic analysis suggested FA and ψ could identify stenosis patients with mild-to-moderate symptoms with a relatively high sensitivity and specificity. CONCLUSIONS: The results of this study support the potential use of DTI as a biomarker for predicting functional impairment in patients with cervical spondylosis.

Study design

A single-center magnetic resonance spectroscopy (MRS) imaging and surgical outcome study involving 16 patients with cervical spondylotic myelopathy (CSM).

Objective

In the present study, we assess the utility of MRS to quantify metabolic changes within the spinal cord and predict surgical outcome in CSM patients.

Summary of background data

MRS is an advanced spinal imaging modality that can provide pertinent metabolic and biochemical information regarding spinal cord function. Previous studies have demonstrated significant abnormalities in specific cellular metabolite concentrations in CSM patients.

Methods

Sixteen patients with CSM were evaluated. Single voxel MRS was performed in the cervical cord. N-acetyl-aspartate (NAA) and choline metabolite concentration ratios with respect to creatine were quantified, as well as the presence or absence of a lactate peak. The modified Japanese Orthopaedic Association (mJOA) scale was used as the functional assessment measure. Correlation of MRS metabolites with change in mJOA score was performed.

Results

The mean follow-up time was 19 months. There was a statistically significant improvement between mean preoperative and postoperative mJOA score after surgery (P<0.0001). The NAA/Cr ratio demonstrated a significant relationship to the change in mJOA score after surgery (P=0.0479; R=0.2513). The Cho/NAA ratio demonstrated an even stronger correlation with the change in mJOA score after surgery (P=0.0065; R=0.4219). Neither the Cho/Cr ratio, nor the presence of a lactate peak or T2-weighted signal change was significantly correlated with change in mJOA score after surgery.

Conclusions

MRS is a novel, noninvasive imaging modality that provides pertinent information regarding spinal cord cellular and metabolic function. In a cohort of operatively treated CSM patients, the NAA/Cr and Cho/NAA ratios were predictive of neurological outcome, as both were significantly associated with change in mJOA score after surgery.

Purpose

To outline the pathogenesis of cervical spondylotic myelopathy (CSM), the correlative abnormalities observed on standard magnetic resonance imaging (MRI), the biological implications and current status of diffusion tensor imaging (DTI), and MR spectroscopy (MRS) as clinical tools, and future directions of MR technology in the management of CSM patients.

Methods

A systematic review of the pathogenesis and current state-of-the-art in MR imaging technology for CSM was performed.

Results

CSM is caused by progressive, degenerative, vertebral column abnormalities that result in spinal cord damage related to both primary mechanical and secondary biological injuries. The T2 signal change on conventional MRI is most commonly associated with neurological deficits, but tends not to be a sensitive predictor of recovery of function. DTI and MRS show altered microstructure and biochemistry that reflect patient-specific pathogenesis.

Conclusion

Advanced imaging techniques, including DTI and MRS, show higher sensitivity to microstructural and biochemical changes within the cord, and may aid in management of CSM patients.